Clinical Trial Update: Pilot Assessment of the Effects of Bardoxolone Methyl on Renal Perfusion, Systemic Haemodynamics and Cardiac Function in Patients With Chronic Kidney Disease and Type 2 Diabetes [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating Bardoxolone methyl in chronic kidney disease and type 2 diabetes has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease
• Type 2 Diabetes Mellitus

Drugs mentioned

• Bardoxolone Methyl (bardoxolone methyl)

Snippet

Sponsor: Biogen | Conditions: Renal Insufficiency, Chronic, Diabetes Mellitus, Type 2 | Phase 1 | Status: WITHDRAWN